AUTHORS
James Godfrey, MD, Geoffrey Shouse, DO PhD2, John Baird, MD3, Swetha Thiruvengadam, MD4, Victor Orellana-Noia, MD5, Matthew Mei I, MD6, Lu Chen, PhD7, Diane Lynne Smith, PhD8, Alex Francisco Herrera, MD9, Avyakta Kallam, MBBS10
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
ABSTRACT
Background: Central nervous system lymphoma (CNSL) is a disease of significant unmet need. Currently, long-term survival is observed in only 40-50% of patients (pts), and standard treatments including high intensity chemotherapy and whole brain radiation are associated with significant toxicities and neurocognitive decline. Patients with methotrexate (MTX)-resistant CNSL have particularly poor outcomes with standard treatments such as Bruton’s Tyrosine Kinase (BTK) inhibitors often eliciting only short-term responses and a median progression-free survival of only 4-5 months. In contrast, we have previously demonstrated that the CD20xCD3 bispecific antibody, glofitamab, can cross the blood-brain barrier, redirect immune cells to CNS tumors, and safely induce long-term complete responses in a small clinical case series of CNSL pts. Based on these findings, we developed a phase 1b study to prospectively evaluate the safety and preliminary efficacy of glofitamab in CNSL.
Methods: This is a phase 1b study with a safety lead-in to evaluate glofitamab in CNSL (NCT#06922604). Eligible pts were either MTX-resistant or MTX-ineligible. Treatment consisted of standard glofitamab treatment per package insert dosing. Pts received 1,000 mg of obinutuzumab on C1D1. Glofitamab was given as step-up doses during C1 (D8, 2.5 mg; D15, 10 mg), followed by 30 mg on D1 of C2-12 (21-day cycles). Adverse events (AEs) including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) were assessed by CTCAE/ASTCT. Response was assessed by IPCG criteria. Complete response/unconfirmed (CRu) was defined as per IPCG response criteria as any pt fulfilling the criteria for CR but continued with corticosteroid treatment or any pt with a small but persistent enhancing abnormality on MRI related to biopsy or focal hemorrhage. The primary endpoint was unacceptable toxicity during the first 2 cycles. The secondary endpoint was to assess preliminary efficacy, including overall response rate (ORR) and CR rate.
Results: As of July 31, 2026, 12 pts have enrolled. The median age is 62 (range, 36-86). Median number of prior treatments is 4 (range, 1-5), including 6 pts with prior CAR-T or stem cell transplant. Eight pts (67%) were refractory to their last line of therapy. Eight pts had primary CNSL (PCNSL) and 4 had secondary CNSL (SCNSL). The CNS distribution of disease included 9 brain parenchyma, 1 ocular, 1 leptomeningeal, and 1 with concurrent brain parenchyma and leptomeningeal disease. Eleven pts had disease confined to the CNS and 1 pt had synchronous CNS and systemic disease. Median follow-up is 6.5 months. Median number of glofitamab treatment cycles received is 9 (range 4-12). During the initial 6 pt safety lead-in, there was no unacceptable toxicity identified. Among all 12 pts, none have discontinued treatment due to AEs. CRS was observed in 3 pts (Gr 1: 25%) and there were no cases of ICANS. Notable AEs included hematologic toxicity (Gr 3/4 neutropenia: 33%), infusion-related reactions (Gr 2: 17%), and infection (Gr 2: 8%). One pt developed grade 2 tumor flare consisting of transient worsening of their pre-existing right-sided hemiplegia. Symptoms resolved to baseline within 3 days of corticosteroid treatment and the pt successfully resumed treatment with a significant reduction in the size of the lesion on serial imaging. Investigator-assessed ORR/CR+CRu rate is 75% (9/12) and 50% (6/12), respectively. Biopsies were performed on the two pts with a best response of progressive disease, and both pts were noted to have CD20-negative lymphoma at the time of progression. Responses occurred in both PCNSL and SCNSL, and in those with brain parenchyma, ocular, and leptomeningeal disease. All responses were ongoing at data cutoff (range, 4-12 months) with no pt proceeding to consolidative therapy (CAR T cells, hematopoietic stem cell transplant, etc). Correlative analyses, including pharmacokinetic and pharmacodynamic data from the serum and cerebrospinal fluid will be presented at the meeting.
Conclusions: This phase 1b study represents the first prospective results of a BsAb for CNSL. Initial findings indicate glofitamab has promising early activity in CNSL with a manageable safety profile. These results support the further development of glofitamab for CNSL as monotherapy and potentially in combination with other CNS-penetrant therapies in the future.
DISCLOSURES
James Godfrey, MD: No relevant conflicts of interest to declare.